|
Name |
Anhydrocochlioquinone A
|
| Molecular Formula | C30H42O7 | |
| IUPAC Name* |
[(2S,3R,4S)-2-[(3R,4aR,6S,12bR)-3-(2-hydroxypropan-2-yl)-6,12b-dimethyl-8,11-dioxo-2,3,4a,5,6,6a-hexahydro-1H-pyrano[3,2-a]xanthen-9-yl]-4-methylhexan-3-yl] acetate
|
|
| SMILES |
CC[C@H](C)[C@H]([C@@H](C)C1=CC(=O)C2=C(C1=O)OC3[C@H](C[C@@H]4[C@@](C3=C2)(CC[C@@H](O4)C(C)(C)O)C)C)OC(=O)C
|
|
| InChI |
InChI=1S/C30H42O7/c1-9-15(2)26(35-18(5)31)17(4)19-14-22(32)20-13-21-27(37-28(20)25(19)33)16(3)12-24-30(21,8)11-10-23(36-24)29(6,7)34/h13-17,23-24,26-27,34H,9-12H2,1-8H3/t15-,16-,17-,23+,24+,26+,27?,30+/m0/s1
|
|
| InChIKey |
CBLRPZZCLBREIA-YYRMTXNWSA-N
|
|
| Synonyms |
Anhydrocochlioquinone A; CHEBI:182181; [(2S,3R,4S)-2-[(3R,4aR,6S,12bR)-3-(2-hydroxypropan-2-yl)-6,12b-dimethyl-8,11-dioxo-2,3,4a,5,6,6a-hexahydro-1H-pyrano[3,2-a]xanthen-9-yl]-4-methylhexan-3-yl] acetate
|
|
| CAS | NA | |
| PubChem CID | 134723194 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 514.6 | ALogp: | 4.3 |
| HBD: | 1 | HBA: | 7 |
| Rotatable Bonds: | 7 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 99.1 | Aromatic Rings: | 4 |
| Heavy Atoms: | 37 | QED Weighted: | 0.39 |
| Caco-2 Permeability: | -5.022 | MDCK Permeability: | 0.00002350 |
| Pgp-inhibitor: | 0.728 | Pgp-substrate: | 0.993 |
| Human Intestinal Absorption (HIA): | 0.39 | 20% Bioavailability (F20%): | 0.933 |
| 30% Bioavailability (F30%): | 0.992 |
| Blood-Brain-Barrier Penetration (BBB): | 0.769 | Plasma Protein Binding (PPB): | 97.74% |
| Volume Distribution (VD): | 1.704 | Fu: | 3.62% |
| CYP1A2-inhibitor: | 0.054 | CYP1A2-substrate: | 0.084 |
| CYP2C19-inhibitor: | 0.033 | CYP2C19-substrate: | 0.502 |
| CYP2C9-inhibitor: | 0.22 | CYP2C9-substrate: | 0.327 |
| CYP2D6-inhibitor: | 0.053 | CYP2D6-substrate: | 0.073 |
| CYP3A4-inhibitor: | 0.765 | CYP3A4-substrate: | 0.792 |
| Clearance (CL): | 2.439 | Half-life (T1/2): | 0.631 |
| hERG Blockers: | 0.003 | Human Hepatotoxicity (H-HT): | 0.048 |
| Drug-inuced Liver Injury (DILI): | 0.395 | AMES Toxicity: | 0.013 |
| Rat Oral Acute Toxicity: | 0.978 | Maximum Recommended Daily Dose: | 0.975 |
| Skin Sensitization: | 0.731 | Carcinogencity: | 0.051 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.38 |
| Respiratory Toxicity: | 0.94 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC004573 | ![]() |
0.633 | D02IQY | ![]() |
0.232 | ||
| ENC000943 | ![]() |
0.613 | D09WYX | ![]() |
0.230 | ||
| ENC005797 | ![]() |
0.532 | D0F7NQ | ![]() |
0.224 | ||
| ENC004571 | ![]() |
0.522 | D0K7LU | ![]() |
0.223 | ||
| ENC004251 | ![]() |
0.481 | D08BDT | ![]() |
0.223 | ||
| ENC001862 | ![]() |
0.471 | D0W2EK | ![]() |
0.222 | ||
| ENC004572 | ![]() |
0.467 | D03ZZK | ![]() |
0.222 | ||
| ENC002182 | ![]() |
0.467 | D04SFH | ![]() |
0.219 | ||
| ENC002674 | ![]() |
0.455 | D0I2SD | ![]() |
0.219 | ||
| ENC004570 | ![]() |
0.454 | D0H0ND | ![]() |
0.215 | ||